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Abstract
Myeloproliferative neoplasms (MPNs) operationally include essential thrombocythemia, polycythemia vera, primary myelofibrosis (PMF), and prefibrotic PMF. All 4 MPN variants might progress into blast-phase disease (MPN-BP). For essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving TP53 and EZH2 (for expansion of gene symbols, see www.genenames.org); for polycythemia vera, advanced age, leukocytosis, abnormal karyotype, mutations involving SRSF2 and IDH2, and treatment with pipobroman, chlorambucil, or P32; and for PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, CEBPA, and SH2B3. The reported median survival figures for MPN-BP range from 1.5 to 2.5 months in patients treated with supportive care only, from 2.5 to 10 months in those receiving hypomethylating agents or low-dose chemotherapy, and from 3.9 to 9.4 months in those receiving induction chemotherapy. Three-year survival after allogeneic stem cell transplant was reported in 16% to 33% of patients. These observations validate the extremely poor prognosis associated with MPN-BP and the lack of effective drug therapy and highlight the need for urgent assessment of therapeutic values of investigational agents. In the meantime, affected patients might be best served with aggressive chemotherapy followed by allogeneic stem cell transplant after adequate blast clearance.
M
yeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by proliferative bone marrow with varying degrees of reticulin/ collagen fibrosis, extramedullary hematopoiesis, abnormal peripheral blood count, and constitutional symptoms that are presumed to be secondary to abnormally expressed inflammatory cytokines.
1,2 The classical categories of MPN consists of chronic myeloid leukemia, primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV). Chronic myeloid leukemia is invariably associated with a specific genetic abnormality (BCR-ABL1) (for expansion of gene symbols, see www. genenames.org) 3, 4 ; accordingly, the other MPNs are operationally labeled as "BCR-ABL1enegative MPN," and the World Health Organization (WHO) classification system currently recognizes 4 variants of BCR-ABL1enegative MPN: ET, PV, PMF, and prefibrotic PMF. 5 There is considerable overlap among the 4 MPN variants in terms of symptomatology, laboratory findings, bone marrow morphology, and mutations, however, with marked differences in natural history and survival outcomes. 5 Accordingly, diagnostic accuracy is prognostically relevant, especially in terms of differentiating WHO-defined ET from prefibrotic PMF and masked PV, which displays a higher risk of leukemic transformation. 6, 7 In general, the natural history of MPN might be interrupted by thrombohemorrhagic complications 8 or disease transformation into post-ET or post-PV myelofibrosis (MF) 9 or post-MPN acute leukemia, also known as blast-phase myeloproliferative neoplasms (MPN-BP). 10, 11 The typical definition of MPN-BP includes the documentation of 20% or more blasts in the peripheral blood or bone marrow. 12 However, discordance in the content of peripheral blood vs bone marrow blasts is often seen. 13 The propensity for leukemic transformation in MPN varies according to the MPN variant and is highest in PMF, with an incidence of 10% to 20% in the first 10 years of the disease [14] [15] [16] ; lower in PV, with an estimated risk of 2.3% at 10 years and 7.9% at 20 years 17 ; and lowest in ET, with less than 1% in the first decade of the disease. 6, 18 This varying incidence of MPN-BP was recently highlighted in a large study by Tefferi et al. 10 CHARACTERISTICS OF MPN-BP Blast-phase myeloproliferative neoplasms commonly involve the myeloid lineage with rare involvement of the lymphoid lineage. The characteristics of MPN-BP have been reported to be different, both morphologically and cytogenetically, from primary (de novo) acute myeloid leukemia (AML). According to the French-American-British (FAB) classification of AML, erythroleukemia (FAB-M6) and megakaryoblastic leukemia (FAB-M7) were the most common subtypes reported in MPN-BP.
14,19 A Mayo Clinic study of patients with PMF found M7 (25.4%) to be the most common subtype followed by M0 (22.4%) and M2 (17.9%). 19 The incidence of AML in post-ET or post-PV MF is similar to that of post-PMF AML. 19 Patients with PV and ET can also directly develop AML without going through the fibrotic phase of the disease. 16, 20 A karyotype in MPN-BP is often complex, and a favorable karyotype is infrequent. Common mutations described in MPN-BP include JAK2, IDH1/2, TP53, ASXL1, and TET2, whereas their counterparts in primary AML include N/KRAS, DNMT3a, NPM1, and FLT3. [21] [22] [23] [24] A study that analyzed genetic information in paired samples of chronic MPN-BP reported acquisition of TET2 mutation during blast transformation and presence of ASXL1 in both phases of the disease.
22 JAK2 mutations are important in MPN pathogenesis, and clonal changes in JAK2 clones, during leukemic transformation, have been observed with acquisition of new mutations and, in certain instances, loss of the prevailing mutations. 25, 26 
RISK FACTORS FOR LEUKEMIC TRANSFORMATION IN MPN
Various clinical and genetic risk factors have been identified as being useful in predicting leukemic transformation in MPN (Table 1) .
RISK FACTORS FOR LEUKEMIC TRANSFORMATION IN PMF
Conventional drug therapies have not resulted in prolongation of survival in PMF, and allogeneic stem cell transplant (ASCT) remains the definitive treatment for purposes of cure or prolongation of survival. Accordingly, identification of risk factors for inferior overall and leukemia-free survival is a critical step in the management of patients with PMF or post-ET or post-PV MF.
In a study of 311 patients with PMF, independent risk factors for leukemic transformation included circulating blast of more than 3% and platelet count of less than 100Â10 9 /L. 37 The same study also found no increased leukemogenicity from treatment with hydroxyurea, thalidomide, or many other drugs, although a potential detrimental effect from erythropoiesis stimulating agents, and danazol was suggested. Using the aforementioned 2 risk factors, the rate of leukemic transformation was only 6% in the absence of both risk factors and 18% in the presence of one or both risk factors. Leukocytosis (>30Â10 9 /L) was also identified as a risk factor for leukemic transformation in another study. 35 In a study by Passamonti et al, 31 red blood cell (RBC) transfusion need was also identified as an independent risk factor for leukemic transformation, with an incidence of leukemic transformation at 7.4Â100 persons per year in RBC-transfused patients vs 1.5Â100 persons per year in nontransfused patients (P<.001). Other reported risk factors for leukemic transformation include increased serum interleukin 8 levels, 38 C-reactive protein level of greater than 7 mg/L, age greater than 65 years, and peripheral blast count of more than 1%. 30 The International Prognostic Scoring System 45 and the Dynamic International Prognostic Scoring System (DIPSS) 46 are currently used to risk stratify patients with PMF and predict survival. The DIPSS was further modified to DIPSS plus 41 by including 9 /L as being the most important: patients with no risk factors had a risk of leukemic transformation at 5 years of 6% and at 10 years of 12%, whereas the risk was substantially higher in patients with 1 or more risk factors at 18% and 31% at 5 and 10 years, respectively. 35 Subsequent studies have confirmed the adverse effect of specific cytogenetic abnormalities, including monosomal and complex karyotypes. 40 In a study of 793 patients with PMF, the 2-year rate of leukemic transformation was 29.4% in patients with monosomal karyotype compared with 8.3% in patients with complex karyotype. 40 Mutually exclusive driver mutations upregulating the JAK-STAT signaling pathway are frequent in MPN. JAK2 mutations are almost always present in patients with PV, whereas their incidence in PMF and ET is similar and estimated at 60%. 47 In ET and PMF, the remaining 40% of patients harbor either CALR (25%-35%) [48] [49] [50] [51] [52] [53] [54] or MPL (3%-8%) mutations. 47 Approximately 10% to 15% of patients with ET or PMF do not express any one of the aforementioned 3 driver mutations and are often referred to as being "triple negative." 10, 55 The prognostic role of driver mutations, in terms of leukemic transformation, is best recognized for PMF where a higher risk has been associated with triple negative and a lower risk with CALR type 1 mutation status. 10 The most elaborate studies assessing the prognostic role of mutations comes from 2 patient cohorts from Mayo Clinic and Florence, Italy. 44 These studies identified ASXL1, SRSF2, IDH1, or IDH2 mutations as independent risk factors for leukemic transformation. The contribution of these mutations in conferring high risk for leukemic transformation was reported in other studies as well. [56] [57] [58] [59] A Genetics-Based Prognostic Scoring System for PMF that integrated karyotype information and mutation status was recently reported in an abstract form at the American Society of Hematology annual meeting. 60 Cytogenetic risk categorization included very high (monosomal karyotype, inv(3), i(17q), À7/7q-, 11q, or 12p abnormalities), high (complex nonmonosomal 60 Most recently, a Mayo Clinic study of targeted sequencing in PMF identified ASXL1, SRSF2, CBL, and KIT mutations as interindependent risk factors for overall survival. 57 Univariate analysis for leukemiafree survival identified SRSF2, RUNX1, CEBPA, SH2B3, and IDH2 mutations as risk factors, and the first 4 remained significant in that regard in multivariate analysis.
RISK FACTORS FOR LEUKEMIC TRANSFORMATION IN PV
It is now well established that treatment of patients with PV treated with P32, chlorambucil, or pipobroman results in a higher risk of leukemic transformation. 39, 61 Older age, 17, 29 leukocytosis, 17, 62 and abnormal karyotype 17 have also been associated with a higher risk of leukemic transformation. A recent Mayo Clinic study evaluated 133 patients with PV, in which 5.4% had documented leukemic transformation. 63 Sequence variants or mutations in PV other than JAK2, CALR, or MPL were seen in 52.6% of patients. ASXL1, SRSF2, and IDH2 were identified as adverse variants or mutations on the basis of their effect on overall, leukemia-free, or MF-free survival. In particular, SRSF2, IDH2, and RUNX1 mutations were associated with shortened leukemia-free survival in univariate analysis; SRSF2 and IDH2 mutations remained significant in multivariate analysis.
RISK FACTORS FOR LEUKEMIC TRANSFORMATION IN ET
The reported incidence of leukemic transformation in ET has varied from less than 1% to almost 10% in some studies. In this regard, the 10-year rates from earlier studies have ranged from 2.6% 27 to 8.3%-9.7%. 33, 64, 65 More recent studies that have carefully excluded patients with prefibrotic PMF from their study population suggest a remarkably lower rate of less than 1% at 10 years and 2% in 15 years in WHO-defined ET. 6, 66 In regard to risk factors for leukemic transformation in ET, Gangat et al 28 studied 605 consecutive patients and identified anemia with hemoglobin levels below sex-adjusted normal values, extreme thrombocytosis (!1000Â10 9 /L), and age as continuous variables for leukemic transformation; the first 2 risk factors were included in a prognostic model that predicted leukemic transformation, and the particular risk was low at 0.4% when both risk factors were absent and was significantly higher at 4.8% and 6.5% in the presence of one or both risk factors, respectively (P<.001).
Other risk factors for leukemic transformation in ET identified by other studies include leukocytosis (!15Â10 9 /L), 33, 34 extreme thrombocytosis (!1000Â10 9 /L), 6, 28 anemia, 28, 32, 34 older age, 27,28 and increased reticulin content or bone marrow cellularity 6, 34 ; it is possible that the last 2 parameters segregated with incorrectly diagnosed cases with prefibrotic PMF. The effect of cytoreductive drugs in leukemic transformation of patients with ET was examined in several studies including a cohort of 338 patients 67 in which single agent treatment with hydroxyurea or busulfan did not appear to increase the risk of leukemic transformation. Many other retrospective studies have also validated the absence of convincing evidence for drug leukemogenicity in ET, although reports to the contrary are also noted. 33 Regardless, there is general agreement on the absence of controlled data that implicate any 1 drug or combination thereof as being leukemogenic in ET.
More recent studies have examined the role of driver and other mutations in the development of leukemia in ET. Among the 3 MPN-associated driver mutations, MPL mutations have been associated with a higher risk of fibrotic progression but their effect on leukemic transformation was either not apparent 68, 69 or noted during longer-term follow-up. 53 A Mayo Clinic study 63 of targeted sequencing recently identified TP53, EZH2, SRSF2, and IDH2 variants or mutations as being associated with a higher risk of leukemic transformation in univariate analysis; TP53 and EZH2 remained significant in multivariate analysis.
OUTCOME OF PATIENTS WITH MPN-BP
The survival of patients with MPN-BP is generally considered to be extremely poor (Table 2) . This is not unexpected, given its high-risk morphological and cytogenetic features compared with those of both chronic phase MPN and primary AML. Blast-phase myeloproliferative neoplasms are often, but not always, preceded by a fibrotic phase of the disease. 36 In the largest retrospective review of 273 patients with MPN-BP treated with hypomethylating agents (n¼99), high-dose cytarabine (n¼71), or low-dose cytarabine (n¼52), 81 progression-free or overall survival did not differ among the treatment groups; 46 patients subsequently received ASCT, with 27 in complete remission (CR), and median survival was longer in patients in CR vs patients not in CR (35.1 months vs 8.9 months). The authors also noted that treatment outcome had not changed between 1989 and 2016. In a similarly large study, 19 we reported on 91 consecutive cases of MPN-BP; the overall outcome was poor, with a median survival of 2 to 3 months of the subgroup who received induction chemotherapy and responded faring a little better with a median survival of 6.2 months as opposed to 2.7 months of patients who did not respond to treatment (P¼NS). Only 1 patient had received ASCT and survived for more than 2 years. 19 There are several other reports in the literature on MPN-BP. Tam et al 16 reported on 74 patients and also documented responses to AML-like induction chemotherapy that were not, however, durable but with improved survival as compared with supportive care (median, 6 months vs 1.5 months); of note, patients who received ASCT at any point during their treatment had better survival than did those who did not receive ASCT, and the survival advantage was even more evident for early transplant with 73% survival at a median follow-up of 31 months; the authors identified older age, peripheral blasts of 20% or more, and previous splenectomy as independent risk factors for survival. 16 Passamonti et al 20 reported the outcome of MPN-BP after PV and found similar survival between patients who had received AML-like induction chemotherapy (median, 5.6 months) or palliation with low-dose chemotherapy (cytarabine or 6-thioguanine) or supportive care (median, 2.5 months). Noor et al 11 studied 23 patients with MPN-BP, among whom 20 received AML-like induction chemotherapy, with 12 achieving remission; median survival was higher in responding patients at 12.8 months compared with 2.9 months in patients who did not achieve remission; 3 patients underwent ASCT with a median survival of 10.5 months. The authors subsequently scanned the literature and gathered information on 112 patients with MPN-BP to identify favorable risk factors for survival: antecedent diagnosis of ET, absence of complex karyotype, age less than 60 years, and less than 3 previous therapies. In yet another study of 13 patients with MPN-BP, 11 were treated with AML-like induction chemotherapy, with 8 patients achieving complete response, reversal to chronic phase disease, or marrow blast clearance 72 ; 8 patients underwent ASCT, including 5 patients with less than 5% blood and bone marrow blast, 2 patients with peripheral blasts, and 1 patient with more than 5% bone marrow blast; outcome in this small study was better in the absence of excess bone marrow blast, but patients with circulating blasts were still salvageable.
Hypomethylating agents, such as azacitidine and decitabine, have also been shown to have activity in MPN-BP; in a study of 26 patients treated with azacitidine, a 38% response rate (median time to response, 9 months) with an overall median survival of 8 months was reported. 70 In that study, the authors observed better responses in post-ET, as opposed to post-PV, MPN-BP, with no significant difference in overall survival. 70 Another study reviewed patients with MPN-BP treated with azacytidine (75 mg/m 2 ) and found that the observed median survival of 9.9 months was better than that of their historical controls 79 ; once again, the median survival of patients who achieved CR was even better at 19.6 months. In a retrospective comparison to 6 patients treated with decitabine, the 5 who received low-intensity ASCT survived longer, with a median survival of more than 20 months. 13 Similar observations were noted in another study of 14 patients with MPN-BP who received ASCT after first being chemotherapy-induced and 2-year survival was reported at 49%. 71 Badar et al 77 studied the use of decitabine in 21 patients with MPN-BP; 6 patients responded (3 CR, 2 near CR, and 1 partial response), and survival was better in responders vs nonresponders (median, 10.5 months vs 4 months); the authors did not find survival difference between decitabine-treated patients and historical controls treated with AML-like induction chemotherapy without ASCT.
Kennedy et al 74 adopted an approach of using curative intent treatment with induction chemotherapy followed by ASCT in fit and transplant-eligible patients. Seventy-five patients were included in the study, with 39 patients receiving AML-like induction chemotherapy followed by ASCT in eligible patients (17 of 39). The 36 other patients were treated with noncurative intent using hypomethylating agents, novel agents, or supportive care. Two-year survival was superior at 25.6% vs 3.1% in patients treated with curative intent. Furthermore, median survival was impressive at 47 months in patients who received ASCT and was not affected by the type of conditioning regimen. Induction chemotherapy without ASCT was unable to induce long-term remissions and resulted in a median survival of 9.4 months. The transplant cohort and the induction chemotherapy arm with responses but without transplant were compared, and survival was significantly better in the transplant group (2-year survival of 47% vs 15%; P¼.03). The median survival for low-intensity regimens was 6.6 months. This study further stressed the importance of ASCT as an adjunct to induction chemotherapy.
The MPN Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation studied 46 patients with MPN-BP who received ASCT. 75 At a median follow-up of 37.4 months, progression-free survival and overall survival at 3 years were 26% and 33%, respectively. The major determinant of survival after ASCT was achievement of CR before transplant (69% vs 22%; P¼.008). A study in France analyzed the outcomes of ASCT in patients with MPN-BP or myelodysplastic syndrome (MDS)/MPN-BP 76 ; 60 patients were studied and overall survival and leukemia-free survival at 3 years were 16% and 9%, respectively. As expected, outcome was better in patients receiving transplant in CR, while intensity of the conditioning regimen did not affect survival. 76 A Canadian MPN group conducted a study to evaluate the survival effect of ASCT in patients with MF previously exposed to JAK inhibitors 80 ; their patient cohort of 100 included 13 who progressed into MPN-BP while receiving JAK inhibitor; patients with MPN-BP received AML-like induction chemotherapy or hypomethylating agents before transplant; 2-year post-ASCT survival was worst in patients with MPN-BP (32%), and the poor outcome was attributed to a higher relapse rate. In regard to ruxolitinib activity in MPN-BP, a phase 2 study was conducted in refractory AML, including 18 patients with MPN-BP and exhibited limited activity. 73 
INVESTIGATIONAL AGENTS
Blast-phase myeloproliferative neoplasms are relatively resistant to conventional chemotherapy with the only curative hope being ASCT, as discussed above, necessitating the need to develop novel therapies. Bromodomain and extra terminal domain inhibitors (BETis) target epigenetic proteins in cancer and were studied in patient-derived MPN blast progenitor cells and exhibited activity inducing apoptosis and inhibiting growth 82 ; furthermore, synergism was observed when BETis were combined with ruxolitinib. In another study, combination of BETi with heat shock protein 90 inhibitor exerted effects on ruxolitinib-persisting or ruxolitinib-resistant MPN blast cells. This was based on a previous finding reported by this team that heat shock protein 90 inhibitor reduces mutant JAK2, AKT, and c-RAF as well as induces apoptosis in JAKi-resistant MPN blast cells. 83 CPX-351 is a liposome formulation of cytarabine and daunorubicin and recently received breakthrough therapy designation in May 2016 for therapy-related AML or AML with myelodysplasia-related changes. Ex vivo sensitivity using CPX-351 in leukemia cells from different sources exhibited activity against myeloid blasts derived from patients with MPN/MDS overlap. 84 Moreover, the improved survival (median, w10 months with CPX-351 vs w6 months with the standard "7þ3" AML therapy; P¼.005) reported in the relevant phase III trial of CPX-351 involved older patients and high-risk AML, including therapy related and with antecedent MDS or chronic myelomonocytic leukemia. 85 Accordingly, it makes sense to investigate the therapeutic value of CPX-351 in MPN-BP, which happens to be a form of secondary AML and usually affects older patients.
CONCLUSION
The prognosis of MPN-BP remains dismal and appears to be worse than that of primary AML. Drug therapy alone, although capable of inducing CRs in a minority of patients, is ineffective in securing long-term remissions. Furthermore, despite increasing information on mutational repertoire in MPN-BP, the promise for targeted therapy in the near future is currently slim. Durable remissions have been noted in few patients who managed to receive ASCT, but the overall experience with the particular treatment modality has been less than impressive. It is possible that one can reduce the case numbers with MPN-BP using MPN treatment that modifies the natural history of disease, but the particular scenario has yet to be realized. Current prognostic models for MPN are useful in predicting leukemic transformation, and incorporation of molecular information might lead to further refinement of these models. For now, the only hope for cure or long-term remission in MPN-BP remains ASCT, and every effort should be made to identify patients with MPN who are at high risk for leukemic transformation so that they can be offered treatment with ASCT sooner rather than later. The Symposium on Neoplastic Hematology and Medical Oncology will continue in an upcoming issue.
